A new treatment approach for Alzheimer's disease using a special protein that can enter the brain.
A Brain Penetrating Bi-functional Transferrin Receptor Antibody-TNF-alpha Decoy Receptor Fusion Protein for Alzheimer's Disease
This study is exploring a new treatment for Alzheimer's disease that uses a special protein designed to cross into the brain and tackle multiple problems related to the condition, aiming to help improve care for those affected.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Chapman University NIH-funded |
| Lab location | 1 site (Orange, United States) |
| Project ID | NIH-10833042 on NIH RePORTER |
What this research studies
This research investigates a novel therapeutic approach for Alzheimer's disease by developing a fusion protein that can penetrate the blood-brain barrier. The protein combines a decoy receptor for TNF-α, which is involved in the disease's pathology, with an antibody that helps transport it into the brain. By targeting multiple aspects of Alzheimer's disease rather than a single pathological event, this approach aims to improve treatment outcomes. The study focuses on the effectiveness of this brain-penetrating protein in preclinical models of Alzheimer's disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease who may benefit from innovative therapeutic strategies.
Not a fit: Patients with early-stage Alzheimer's disease or those who do not have a confirmed diagnosis may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective treatment for Alzheimer's disease that addresses multiple disease mechanisms.
How similar studies have performed: While similar approaches targeting the blood-brain barrier have been explored, this specific method of using a TNF-α decoy receptor fusion protein is novel and has not been previously tested.
Where this research is happening
Orange, United States
- Chapman University — Orange, United States (Active)
Researchers
- Principal investigator: Sumbria, Rachita — Chapman University
- Study coordinator: Sumbria, Rachita
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.